RCMNY
FBRX icon

Rubric Capital Management (New York)’s Forte Biosciences FBRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-289
Closed -$723K – 65
2019
Q2 		$723K Hold
289
– – 0.06% 54
2019
Q1 		$1.18M Buy
+289
New +$1.12M 0.11% 58

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rubric Capital Management (New York)'s FBRX Position: Q3 2019 in Review

Rubric Capital Management (New York) sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 289 shares — an estimated $723K sold.

Rubric Capital Management (New York) first reported a position in FBRX in Q1 2019 and held it in 2 quarters. The position peaked at $1.18M in Q1 2019. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Rubric Capital Management (New York) reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 289 Forte Biosciences shares in Q3 2019, an estimated $723K.
  • Rubric Capital Management (New York) first reported a position in Forte Biosciences in Q1 2019 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s Forte Biosciences position peaked at $1.18M in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2019, filed 14 Nov 2019.